JonesTrading Welcomes Boris Peaker, PhD, CFA as New Biotechnology Managing Director

JonesTrading Appoints Boris Peaker, PhD, CFA as Managing Director

In a significant move to enhance its healthcare research capabilities, JonesTrading Institutional Services LLC, a prominent investment banking firm, has appointed Boris Peaker, PhD, CFA, as its new Managing Director and Biotechnology Analyst. This announcement was made on April 7, 2026, amidst the growing importance of biotechnology within the healthcare sector.

About Boris Peaker

Dr. Peaker is no stranger to the biotechnology field, boasting over 20 years of dedicated experience as an analyst and industry consultant. His impressive track record includes a decade-long tenure at TD Cowen, where he was instrumental in establishing the firm's comprehensive biotechnology coverage. Prior to that role, he spent three years with Oppenheimer, along with experience from several boutique research firms, thereby enriching his understanding of the equity markets and their dynamics within the biotechnology domain.

Dr. Peaker is well-equipped for his new role with an academic background that features a PhD in Biophysics from Stanford University and dual undergraduate degrees in Physics and Chemistry from Stony Brook University. Additionally, he holds the Chartered Financial Analyst (CFA) designation, further solidifying his credentials in financial analysis and investment.

Expanding JonesTrading's Biotech Research

As the Managing Director of Biotechnology, Dr. Peaker will lead coverage specific to biotechnology companies within the healthcare sector. His work will concentrate on cutting-edge technologies, particularly in oncology, immunology, and genetic medicine—fields that are witnessing lightning-fast advancements and significant investor interest.

Alan Hill, the CEO of JonesTrading, expressed enthusiasm about Dr. Peaker's appointment, stating, "This is an important step as we continue to broaden our healthcare research platform. Biotechnology remains a critical and rapidly evolving sector for our clients, and Boris' expertise will ensure we deliver the depth of insight needed to navigate it successfully."

Hans Vitzthum, Director of Research at Jones, echoed this sentiment by highlighting Dr. Peaker’s commendable scientific foundation and remarkable ability to derive actionable insights from complex clinical data. His unique skills in identifying key inflection points within the biotechnology sector are expected to significantly bolster the firm's research capacity.

JonesTrading: A Leader in Investment Banking

Founded in 1975, JonesTrading Institutional Services has made a name for itself as a leading full-service investment banking firm. The company is recognized for its innovative solutions and deep expertise in various sectors, including capital markets, mergers & acquisitions, and strategic advisory services. It holds a strong reputation as a prominent liquidity provider and has pioneered methods in block trading.

With this new addition to their team, JonesTrading is poised to enhance its offerings to institutional investors, ensuring clients receive tailored strategies and insightful research that align with their investment goals.

In conclusion, the appointment of Boris Peaker marks a proactive strategy by JonesTrading to solidify its position in the biotechnology sector and deliver exceptional service to its clients. As the landscape of investment shifts and expands, having a leader like Dr. Peaker is a crucial step towards staying ahead in the market.